Succinylated D-Type Neuropeptide Integrated with Iron-Based Probes for Regulating Mitochondrial Function and...

Area of Science:

• Biochemistry
• Molecular Biology
• Nanotechnology

Background:

• Posttranslational modifications like succinylation are crucial for cellular homeostasis and metabolism.
• Targeting mitochondrial function to induce apoptosis in breast cancer is a significant therapeutic challenge.

Purpose of the Study:

• To design a novel succinylated neuropeptide-based nanoprobe for targeted breast cancer therapy.
• To investigate the probe's mechanism involving SIRT5-mediated desuccinylation and mitochondrial disruption.
• To evaluate the nanoprobe's diagnostic potential using magnetic resonance imaging (MRI).

Main Methods:

• Design of a succinylated D-type neuropeptide integrated with an iron-based probe.
• Targeted delivery to breast cancer cells via Y1 receptor-mediated endocytosis.
• SIRT5-catalyzed desuccinylation within mitochondria, leading to probe aggregation and mitochondrial dysfunction.
• Assessment of gene expression related to inflammation and ferroptosis.
• MRI to monitor mitochondrial perturbations via contrast shift from T1 to T2.

Main Results:

• The nanoprobe selectively targets breast cancer cells and induces apoptosis through mitochondrial disruption.
• SIRT5-mediated desuccinylation triggers probe aggregation, altering mitochondrial membrane potential and electron transport.
• Upregulation of inflammation and ferroptosis genes suggests an enhanced antitumor microenvironment.
• MRI successfully visualizes mitochondrial perturbations in real-time due to the T1-to-T2 contrast shift.

Conclusions:

• The developed nanoprobe offers a versatile platform for breast cancer diagnosis and therapy.
• SIRT5-mediated desuccinylation is a viable strategy for targeted mitochondrial disruption.
• The nanoprobe demonstrates potential for real-time monitoring of therapeutic response via MRI.